Research and Development Expenses Breakdown: Sarepta Therapeutics, Inc. vs Xenon Pharmaceuticals Inc.

Biotech R&D: Sarepta vs. Xenon - A Decade of Growth

__timestampSarepta Therapeutics, Inc.Xenon Pharmaceuticals Inc.
Wednesday, January 1, 20149423100011768000
Thursday, January 1, 201514639400015152000
Friday, January 1, 201618827200019828000
Sunday, January 1, 201716670700025573000
Monday, January 1, 201840184300023634000
Tuesday, January 1, 201956090900038845000
Wednesday, January 1, 202072234300050523000
Friday, January 1, 202177118200075463000
Saturday, January 1, 2022877090000105767000
Sunday, January 1, 2023877387000167512000
Loading chart...

Igniting the spark of knowledge

A Decade of Innovation: R&D Spending in Biotech

In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Sarepta Therapeutics, Inc. and Xenon Pharmaceuticals Inc. have demonstrated contrasting strategies in their R&D investments.

From 2014 to 2023, Sarepta Therapeutics has consistently increased its R&D expenses, peaking in 2022 with a staggering 877 million dollars, reflecting a nearly tenfold increase from 2014. This aggressive investment underscores Sarepta's dedication to advancing its pipeline of genetic medicine. In contrast, Xenon Pharmaceuticals, while also increasing its R&D spending, has done so at a more modest pace, reaching 168 million dollars in 2023, a fourteenfold increase from 2014.

These trends highlight the varying approaches within the biotech sector, where strategic R&D investments can significantly influence a company's trajectory and impact on healthcare innovation.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025